Iambic Therapeutics, Inc.
Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
Funding history
About Iambic Therapeutics, Inc.
How much funding has Iambic Therapeutics, Inc. raised?
Iambic Therapeutics, Inc. has raised $325.4M in total funding.
Where is Iambic Therapeutics, Inc. headquartered?
Iambic Therapeutics, Inc. is headquartered in San Diego, CA.
What does Iambic Therapeutics, Inc. do?
Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
What problem does Iambic Therapeutics, Inc. solve?
Traditional drug discovery is slow at converting molecular designs into differentiated drug candidates, including for targets considered undruggable.
What's Iambic Therapeutics, Inc.'s solution?
Iambic runs a 'molecular superintelligence' platform pairing AI models with high-throughput experimentation to design and test novel drug candidates on a weekly cycle.
What makes Iambic Therapeutics, Inc. different?
They point to proprietary multimodal transformer and co-folding AI technologies (Enchant and NeuralPLexer) that let them deliver a pipeline of differentiated clinical candidates years faster than the industry standard.
What makes Iambic Therapeutics, Inc. notable?
Co-founded by Tom Miller, PhD (who also co-founded genomics company Veracyte), and backed by Nvidia and Cathie Wood's Ark Investment Management.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.